Cover Image
市場調查報告書

沙眼衣原體感染:開發中產品分析

Chlamydia Infections - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 200439
出版日期 內容資訊 英文 68 Pages
訂單完成後即時交付
價格
Back to Top
沙眼衣原體感染:開發中產品分析 Chlamydia Infections - Pipeline Review, H2 2017
出版日期: 2017年09月19日 內容資訊: 英文 68 Pages
簡介

沙眼衣原體感染是因細菌而引起的傳染性病。症狀有排尿時的刺痛感,陰莖和陰道有膿一般的分泌物,下腹部疼痛,非經期的出血及疼痛,睪丸週邊的腫起等。原因有年齡,非特定多數的性交對象,性感染疾病的病史等。治療方法有使用抗生素和止痛藥等。

本報告提供沙眼衣原體感染的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等資訊,為您概述為以下內容。

目錄

簡介

沙眼衣原體感染概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

研究中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

研究中的產品:各大學/研究機關

開發治療藥的企業

  • Abera Bioscience AB
  • Genocea Biosciences, Inc.
  • Lead Discovery Center GmbH
  • Merck & Co., Inc.
  • NanoBio Corporation
  • Prokarium Limited
  • QureTech Bio AB
  • SATT IDF Innov SAS
  • Selecta Biosciences, Inc.
  • SIGA Technologies, Inc.
  • Statens Serum Institut
  • Vault Pharma Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9734IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chlamydia Infections - Pipeline Review, H2 2017, provides an overview of the Chlamydia Infections (Infectious Disease) pipeline landscape.

Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods and pain and swelling around the testicles. Predisposing factors include age, multiple sex partners and history of prior sexually transmitted infection. Treatment includes antibiotics and pain medicine.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chlamydia Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chlamydia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.

Chlamydia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chlamydia Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Chlamydia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chlamydia Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chlamydia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chlamydia Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chlamydia Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chlamydia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chlamydia Infections - Overview
    • Chlamydia Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Chlamydia Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Chlamydia Infections - Companies Involved in Therapeutics Development
    • Abera Bioscience AB
    • Evofem Inc
    • Lead Discovery Center GmbH
    • Merck & Co Inc
    • NanoBio Corp
    • Prokarium Ltd
    • QureTech Bio AB
    • SATT IDF Innov SAS
    • Selecta Biosciences Inc
    • SIGA Technologies Inc
    • Vault Pharma Inc
    • Vaxine Pty Ltd
  • Chlamydia Infections - Drug Profiles
    • Ab-03 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • acALY-18 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Amphora - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia trachomatis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia trachomatis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PEG-2S - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides to Inhibit CPAF for Chlamydia Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Chlamydia Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block Virulence for Chlamydia Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • solithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-669 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPI-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chlamydia Infections - Dormant Projects
  • Chlamydia Infections - Product Development Milestones
    • Featured News & Press Releases
      • Apr 20, 2017: New weapon in fight against antibiotic resistance discovered
      • Dec 02, 2015: NanoBio's Chlamydia Vaccine Improves Clearance of Bacteria and Prevents Pelvic Inflammatory Disease in Mice
      • Aug 03, 2015: New Vaccine For Chlamydia to Use Synthetic Biology
      • Aug 03, 2015: SynbiCITE funds new vaccine for Chlamydia
      • Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection
      • Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Chlamydia Infections, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Chlamydia Infections - Pipeline by Abera Bioscience AB, H2 2017
  • Chlamydia Infections - Pipeline by Evofem Inc, H2 2017
  • Chlamydia Infections - Pipeline by Lead Discovery Center GmbH, H2 2017
  • Chlamydia Infections - Pipeline by Merck & Co Inc, H2 2017
  • Chlamydia Infections - Pipeline by NanoBio Corp, H2 2017
  • Chlamydia Infections - Pipeline by Prokarium Ltd, H2 2017
  • Chlamydia Infections - Pipeline by QureTech Bio AB, H2 2017
  • Chlamydia Infections - Pipeline by SATT IDF Innov SAS, H2 2017
  • Chlamydia Infections - Pipeline by Selecta Biosciences Inc, H2 2017
  • Chlamydia Infections - Pipeline by SIGA Technologies Inc, H2 2017
  • Chlamydia Infections - Pipeline by Vault Pharma Inc, H2 2017
  • Chlamydia Infections - Pipeline by Vaxine Pty Ltd, H2 2017
  • Chlamydia Infections - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Chlamydia Infections, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top